DV
Dividend Vision

AVTX — Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. (AVTX)

Its deepest 1-year drawdown was 44.3%.

This is a single-stock holding in Avalo Therapeutics, a biopharmaceutical company focused on developing therapeutic treatments. The stock does not currently pay dividends, making it unsuitable for income-focused investors seeking regular distributions. This equity holding appeals primarily to growth-oriented investors interested in exposure to the pharmaceutical development sector rather than dividend income.

AVTX key facts

Asset type
Stock
Asset class
Equity
Inception date
10/14/2015
Distribution frequency
None
Last close
$19.59
Market cap
$1,050,611,456
Average volume
388067.0
Beta
0.788
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.41